Literature DB >> 9389549

Morphological changes induced by 6-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800.

A Sourla1, S Luo, C Labrie, A Bélanger, F Labrie.   

Abstract

The present study compares the effects of tamoxifen and EM-800, both administered at the oral daily dose of 100 microg for 6 months, on the uterus, vagina, and mammary gland in the mouse at histopathological examination. Treatment of intact animals with EM-800 resulted in uterine and vaginal atrophy even greater than that achieved after ovariectomy, while the developmental growth of the mammary gland was completely blocked and serum LH was increased. In ovariectomized animals, treatment with EM-800 decreased uterine and vaginal wt below the values observed in control ovariectomized mice while no significant change was observed on serum LH, thus indicating the lack of estrogenic activity of EM-800. Tamoxifen, on the other hand, showed a stimulatory estrogenic-like action on the mouse uterus in both intact and ovariectomized animals, thus resulting in moderate to severe endometrial hyperplasia. These morphological changes were accompanied by a marked stimulation of both the estrogenic and androgenic 17beta-hydroxysteroid dehydrogenase as well as 5alpha-reductase uterine activities. The histological atrophic changes observed in the vagina after tamoxifen treatment were less pronounced than those seen after treatment with EM-800. The agonistic estrogen-like action of tamoxifen was also illustrated by the suppression of serum LH levels in ovariectomized animals. A marked stimulation of the ovarian stroma, accompanied by a significant reduction in folliculogenic activity, was observed after EM-800 or tamoxifen administration, although the interstitial ovarian hyperplasia was more pronounced after EM-800 treatment. While both antiestrogens blocked the developmental growth of the mammary gland, EM-800 showed more potent antiestrogenic activity than tamoxifen. The highly potent and specific antiestrogenic activity of EM-800 suggests that this compound could improve the therapy of breast cancer while avoiding the undesirable stimulation of the endometrium.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389549     DOI: 10.1210/endo.138.12.5560

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.

Authors:  Marian Y Williams-Brown; Sana M Salih; Xia Xu; Timothy D Veenstra; Muhammad Saeed; Shaleen K Theiler; Concepcion R Diaz-Arrastia; Salama A Salama
Journal:  J Steroid Biochem Mol Biol       Date:  2011-05-10       Impact factor: 4.292

Review 2.  Antiestrogens--tamoxifen, SERMs and beyond.

Authors:  K Dhingra
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  Estradiol and tamoxifen regulate NRF-1 and mitochondrial function in mouse mammary gland and uterus.

Authors:  Margarita M Ivanova; Brandie N Radde; Jieun Son; Fabiola F Mehta; Sang-Hyuk Chung; Carolyn M Klinge
Journal:  J Mol Endocrinol       Date:  2013-09-10       Impact factor: 5.098

Review 4.  Therapeutic options for management of endometrial hyperplasia.

Authors:  Vishal Chandra; Jong Joo Kim; Doris Mangiaracina Benbrook; Anila Dwivedi; Rajani Rai
Journal:  J Gynecol Oncol       Date:  2015-12-01       Impact factor: 4.401

5.  Rhaponticin contained Rheum officinale root extract improved Postmenopause symptom of Ovariectomized Rat.

Authors:  Anton Bahtiar; Herlina Tri Setyowati; Retno Rela Mahanani; Azizah Wati; Ade Arsianti; Fadilah Fadilah
Journal:  J Adv Pharm Technol Res       Date:  2021-04-27

6.  Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis.

Authors:  Jesús Loureiro; Pilar Sandoval; Gloria del Peso; Guadalupe Gónzalez-Mateo; Vanessa Fernández-Millara; Beatríz Santamaria; Maria Auxiliadora Bajo; José Antonio Sánchez-Tomero; Gonzalo Guerra-Azcona; Rafael Selgas; Manuel López-Cabrera; Abelardo I Aguilera
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

7.  Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model.

Authors:  Fabia De Oliveira Andrade; Wei Yu; Xiyuan Zhang; Elissa Carney; Rong Hu; Robert Clarke; Kevin FitzGerald; Leena Hilakivi-Clarke
Journal:  Endocr Relat Cancer       Date:  2019-03-01       Impact factor: 5.678

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.